AsiaNet 89464

PMB and CEA Announce the Commissioning of iMiGiNE at Frederic Joliot Hospital (Orsay), Paving the Way for Next Generation Molecular Imaging Diagnostics

PEYNIER, France, May 12, 2021 /PRNewswire=KYODO JBN/ --

An automated radiopharmaceutical production system iMiGiNE has been installed

in Frederic Joliot Hospital (CEA) in Orsay, France and commissioned in December

2020. This disruptive system will revolutionize the radiopharmaceutical

production, access and distribution. iMiGiNE will allow clinical centers to

directly access disease-specific radiopharmaceuticals, otherwise rarely

available, and take a first step towards personalized molecular imaging.

To view the Multimedia News Release, please click:  

https://www.multivu.com/players/uk/8894551-imigine-a-paradigm-shift-in-the-production-of-radiopharmaceuticals/

A shift in paradigm: microfluidic syntheses

iMiGiNE uses groundbreaking technology to produce radiopharmaceuticals: a

single-use lab-on-a-chip device, with onboard precursors and solvents. Offering

lower volumes and higher yields, this versatile microfluidic cassette can be

used for process or tracer development as well as the production of single

doses or small batches. It is integrated in a radiosynthesis box, a closed

system to prevent cross contamination, operated by a robotized arm, and

controlled through a supervision software.

An automated manufacturing process, from radiopharmaceutical selection to a

filled syringe

iMiGiNE combines a cyclotron equipped with a superconducting magnet, making it

more stable and compact, and a robotized radiochemistry to produce the selected

radiopharmaceutical. Operated through a user-friendly supervision software, the

cyclotron produces the selected radioisotope, which is then transferred to the

radiochemistry for radiolabeling.

Unlocking the full potential of precision medicine

Only a few of more than a hundred molecules of clinical interest are used today

in routine PET imaging. Why? Cumbersome processes and infrastructures, and

costly manufacturing operations. Additionally, the use of some radioisotopes

with a short half-life is challenging for smaller centers (110 min for 18F and

only 20 min for 11C). iMiGiNE can break those barriers by relocating the

production of radiopharmaceuticals close to the patient, and ultimately

improving patient care.  

About PMB

PMB is a human-sized company located near Aix-en-Provence, in the south of

France, specialized in the design and manufacture of complex particle

accelerators systems for Medical, Research, Nuclear, Defense and Industry

applications.

Historically, PMB started with the specialty of assembling dissimilar materials

such as metals and ceramics. Since 2010, we have developed complex systems

integrating particle accelerators. Among others, an automated system that

produces in-house PET radiopharmaceuticals and linear accelerators for

non-destructive testing (high-energy radiography), and radiotherapy. PMB is

part of the French industrial group ALCEN.

About CEA

The CEA is a key player in research, development and innovation in four main

areas: energy transition, digital transition, technology for the medicine of

the future and defense and security. The CEA carries out fundamental research

in the fields of Biotechnology and Health, the Physical Sciences, Earth

Sciences and Astronomy, Physics and Nanoscience. Its core objectives are the

production and publication of knowledge and expertise at the highest

international level. In 2019, nearly 3,800 scientific papers were published by

CEA researchers, three-quarters of which were the result of international

collaboration. The CEA draws on all this knowledge to carry out its other

activities.  

For more information about PMB and CEA, please visit www.pmb-alcen.com /

www.cea.fr

Additional information about iMiGiNE can be found at www.imigine.com or follow

PMB-Alcen [www.linkedin.com/company/pmb-alcen] on LinkedIn.  

Video - https://www.youtube.com/watch?v=jOYvDZX-3Rc

Photo - https://mma.prnewswire.com/media/1505470/PMB_Alcen_PET.jpg  

Logo - https://mma.prnewswire.com/media/1505469/PMB_Alcen_Logo.jpg

Contact:

Fatine Slaoui

contact@pmb-alcen.com

+33 4 42 53 13 13

Source : PMB-Alcen